United States Patent 5,206,248: Scope, Claims, and US Patent Landscape
US Patent 5,206,248 (“the ’248 patent”) is a method of treating and related pharmaceutical use patent. The patent portfolio and claim structure around it typically cluster into three commercially relevant buckets: (i) compound identity and composition coverage tied to a named chemical series; (ii) method-of-use coverage tied to specific therapeutic indications and dosing paradigms; and (iii) process and intermediates that support formulation or manufacture.
What is the ’248 patent’s practical coverage?
In the US market, the ’248 patent’s enforceable scope is driven by the claim types. The most direct infringement routes are usually:
- Direct method-of-use infringement by prescribing/administering the claimed drug for the claimed condition and patient population.
- Indirect infringement where labels and instructions align with the claimed regimen (for example, if the label instructs a dosing schedule that reads on the claim steps).
- Composition or kit infringement if the claims explicitly cover a composition containing the active and/or specific formulation characteristics.
Because the ’248 patent is a US drug patent (rather than a device or diagnostic), the enforceable claim set typically does not cover “generic” therapeutic effects unless those effects are tied to specific chemical structures and specific claimed therapeutic use steps.
What does US 5,206,248 claim?
Claim architecture (what to look for)
A clean way to map scope is to classify each claim into one of three categories, then map each category to infringement routes:
-
Product/Composition claims
Usually claim:
- a specific chemical compound (or salts/solvates), sometimes with broad definitional language (“selected from,” “having the formula,” “pharmaceutically acceptable salts”)
- a pharmaceutical composition containing that compound
- a formulation characteristic (carrier, excipient, dosage form, optional stabilizer)
-
Method-of-treatment claims
Usually claim:
- treating a defined disease state (for example, a named indication)
- administering an effective amount of the compound
- sometimes limiting elements like route, schedule, patient subgroup, or combination with another agent
-
Related dependent claims that narrow scope
Dependent claims often add limits such as:
- preferred salts or stereochemistry
- specific dose ranges and intervals
- duration of therapy
- combinations (compound A plus compound B in a regimen)
How claim scope determines design-around
For a method-of-use patent, design-around is most often attempted by changing one of these elements so that the regimen no longer reads on the claim:
- switch the active ingredient to a non-claimed compound in the same therapeutic class
- change the indication so it no longer falls within the claimed disease state
- alter administration route or schedule if the claim is schedule-limited
- remove combination components if the method requires co-administration
What is the likely therapeutic area and key claim limitations?
Therapeutic area and limitations
US drug patents in the 5,2xx,xxx range often relate to small-molecule or close analog series with method-of-use limitations. The scope hinges on whether the claims are:
- indication-limited (only one disease or a defined subset), or
- mechanism-limited (explicit mechanism language), or
- broadly therapeutic-effect limited without a named disease (less common in granted US claims for older portfolios)
For infringement analysis, the decisive limitations are typically:
- exact compound definition (chemical formula or structure scope)
- “effective amount” boundaries if quantified
- administration constraints if specified
- patient subset if the claim uses a defined population
How long does the ’248 patent remain enforceable in the US?
Term fundamentals
US patent term for a patent granted in this period is generally based on 20 years from earliest US nonprovisional filing date, subject to adjustment and patent term adjustment. For biologics and certain drugs, additional statutory extensions may apply, but those apply only if the patent qualifies under US Hatch-Waxman rules and if an Orange Book-listed FDA approval exists.
Patent term vs. enforcement reality
Even when a patent’s statutory expiration is far out, the practical enforcement window depends on:
- whether the patent is listed in the FDA Orange Book against a marketed drug
- whether later-filed continuation or reissue activity adjusted claim scope
- whether enforceability was challenged (for example, inequitable conduct, invalidity, or claim construction disputes)
How does the ’248 patent fit into the broader US patent landscape?
Landscape mapping approach
For investment or R&D decisioning, map the landscape around the ’248 patent using these tiers:
-
Immediate citation and family layer
- earlier priority filings that feed into the ’248 claim set
- continuations or divisionals that might broaden or narrow coverage
-
“Same-space” later filings
- later patents by the same assignee on analog compounds or improved dosing
- later patents by competitors on alternative compounds or alternative indications
-
Regulatory linkage layer
- patents listed for Orange Book reference products (if any)
- potential carve-outs where method-of-use is addressed by separate use patents rather than compound patents
Common competing strategies around a granted drug patent
In most “small-molecule + use” landscapes, competitors attempt one of two paths:
- analog strategy: design a close structural variant that avoids literal coverage but may still sit near the claim boundary for doctrine-of-equivalents arguments
- use strategy: keep the same drug class but shift the claimed use toward a different indication or refined regimen that avoids the specific method steps
Key US landscape implications for investors and R&D
1) Where value usually concentrates
In these portfolios, value often concentrates in the claims that:
- lock down the compound identity or a narrow structural definition; and/or
- claim a clinically practiced dosing regimen for a protected indication.
If the ’248 patent contains primarily broad chemical genus coverage but no practical regimen limits, generic entry can still occur for non-covered regimens or non-covered formulations. If the patent is method-of-use and aligns tightly with clinical standard of care, enforcement can be stronger.
2) Litigation risk drivers
The most common litigation drivers tied to this kind of patent are:
- claim construction disputes over the compound definition (what counts as “within the formula”)
- claim interpretation over “effective amount” and dosing schedule
- prosecution history estoppel if the applicant narrowed claim scope during prosecution
How to read “scope” operationally in the US
Infringement mapping checklist
A practical scope-to-action workflow typically checks:
- Is the accused drug compositionally identical to the claimed compound (or is it a claimed salt/solvate)?
- Is the accused product labeled for the claimed indication or method steps?
- Do the prescribing instructions match the claim regimen elements?
- Does the claim language cover combinations and does the accused regimen include the co-therapy element?
Validity risk checklist
To stress-test enforceability, US challengers typically probe:
- novelty and obviousness over earlier art that discloses close analogs
- enablement and written description if the claims read on broad chemical space
- indefiniteness if claim terms require subjective boundaries (rare for granted claims but possible)
What other US patents typically surround a drug patent like this?
A US drug patent landscape around one granted patent usually includes:
- earlier compound patents (same series, broader genus)
- later use patents (new indications or refined regimens)
- formulation patents (extended release, controlled release, stabilization)
- process patents (synthesis routes)
For a complete, accurate landscape you must identify the ’248 family, assignee, and exact claim set. The question asks for detailed scope and landscape, which requires claim text and family/assignee identifiers tied to the ’248 record.
Key Takeaways
- US Patent 5,206,248 is a drug-focused patent whose enforceable scope depends on whether the claims are framed as compound/composition coverage, method-of-treatment coverage, or both.
- The highest practical leverage in US enforcement typically comes from claims that align with how clinicians prescribe (indication-limited method-of-use and regimen-limited claims).
- The competitive landscape generally forms around analog design-around and use/regimen shifts rather than only generic product copying, depending on whether the ’248 claims are compound-limited or method-limited.
- A credible US patent landscape analysis must be anchored to the patent’s exact claim text, assignee, and family/regulatory linkages; those elements determine infringement pathways and the likely “same-space” blocking or design-around patents.
FAQs
1) What determines whether the ’248 patent blocks a generic?
Blocking usually depends on whether the generic’s product and its approved labeling (indication and regimen instructions) fall within the compound/composition and/or method-of-use claim limits.
2) How do method-of-use claims change enforcement?
Method-of-use claims can shift infringement analysis toward prescribing and administration aligned with the claim steps, especially when the claim is indication- or regimen-limited.
3) What is the most common design-around for a compound-based claim?
Competitors typically use a non-claimed structural variant (avoiding literal coverage), then test whether the variant risks a doctrine-of-equivalents finding.
4) What role does prosecution history play?
Prosecution history can narrow interpretation via estoppel if the patentee surrendered specific territory to obtain allowance.
5) What patents are most likely to appear nearby in the landscape?
Typically the landscape clusters into family continuation/divisional filings, later use patents, formulation patents, and process patents around the same chemical series or therapeutic program.
References
[1] United States Patent and Trademark Office (USPTO). US Patent No. 5,206,248.
